Livio Azzoni
Overview
Explore the profile of Livio Azzoni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1036
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Foulkes A, Azzoni L, Montaner L
Stat Commun Infect Dis
. 2023 Jun;
12(Suppl1):20190018.
PMID: 37288470
Objectives: Exploratory studies that aim to evaluate novel therapeutic strategies in human cohorts often involve the collection of hundreds of variables measured over time on a small sample of individuals....
2.
Tebas P, Lynn K, Azzoni L, Cocchella G, Papasavvas E, Fair M, et al.
AIDS
. 2023 Apr;
37(8):1203-1207.
PMID: 37070542
Objective: The aim of this study was to assess the susceptibility of HIV to two HIV monoclonal antibodies (bnAbs), 3BNC117 and 10-1074, in individuals with chronically antiretroviral therapy (ART) suppressed...
3.
Dube K, Agarwal H, Carter W, Dee L, Taylor J, Roebuck C, et al.
HIV Res Clin Pract
. 2022 Aug;
23(1):76-90.
PMID: 35968737
: HIV cure-directed clinical trials using analytical treatment interruptions (ATIs) require participants to adhere to frequent monitoring visits for viral load tests. Novel viral load monitoring strategies are needed to...
4.
Azzoni L, Giron L, Vadrevu S, Zhao L, Lalley-Chareczko L, Hiserodt E, et al.
J Leukoc Biol
. 2022 Aug;
112(4):733-744.
PMID: 35916053
Opioid use has negative effects on immune responses and may impair immune reconstitution in persons living with HIV (PLWH) infection undergoing antiretroviral treatment (ART). The effects of treatment with μ...
5.
Papasavvas E, Azzoni L, Ross B, Fair M, Howell B, Hazuda D, et al.
AIDS
. 2021 May;
35(12):2051-2054.
PMID: 34049356
We report on the post-hoc analysis of three clinical studies (NCT01935089, NCT00594880 and NCT00051818) with chronically HIV-infected, immune-reconstituted individuals with similar entry criteria, and demographics interrupting antiretroviral therapy (ART) without...
6.
Papasavvas E, Azzoni L, Ross B, Fair M, Yuan Z, Gyampoh K, et al.
Clin Infect Dis
. 2021 Feb;
72(3):495-498.
PMID: 33527127
Accurate characterization of the human immunodeficiency virus (HIV) reservoir is imperative to develop an effective cure. HIV was measured in antiretroviral therapy-suppressed individuals using the intact proviral DNA assay (IPDA),...
7.
Papasavvas E, Azzoni L, Pagliuzza A, Abdel-Mohsen M, Ross B, Fair M, et al.
AIDS Res Hum Retroviruses
. 2020 Dec;
37(6):433-443.
PMID: 33323024
In the pilot NCT01935089 trial, we tested whether pegylated interferon alpha2b (Peg-IFN-α2b) with antiretroviral therapy (ART) was safe and could impact HIV and immune measures in blood and in gut-associated...
8.
Tomescu C, Colon K, Smith P, Taylor M, Azzoni L, Metzger D, et al.
J Leukoc Biol
. 2020 Dec;
PMID: 33289158
Previous literature suggests that acute opioid use results in the functional impairment of the immune response, thereby decreasing resistance to viral infection. Here, we assessed if innate and adaptive immune...
9.
Azzoni L, Metzger D, Montaner L
J Neuroimmune Pharmacol
. 2020 Oct;
15(4):875.
PMID: 33098533
The original version of this article unfortunately contained mistakes.
10.
Azzoni L, Metzger D, Montaner L
J Neuroimmune Pharmacol
. 2020 Sep;
15(4):643-657.
PMID: 32974750
While there is an emerging consensus that engagement of the Mu opioid receptor by opioids may modulate various stages the HIV life cycle (e.g.: increasing cell susceptibility to infection, promoting...